(Q40131139)

17 September 2017

1 reference

title

Immunizations: current controversies (English)

1 reference

17 September 2017

Immunizations: Current controversies (English)

1 reference

https://api.crossref.org/works/10.1016/S0022-3476(82)80686-0

17 September 2023

0 references

V. A. Fulginiti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6288902

17 September 2023

language of work or name

English

0 references

publication date

1 October 1982

1 reference

full work available at URL

17 September 2017

https://api.elsevier.com/content/article/PII:S0022347682806860?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0022-3476(82)80686-0

https://api.elsevier.com/content/article/PII:S0022347682806860?httpAccept=text/plain

17 September 2023

1 reference

https://api.crossref.org/works/10.1016/S0022-3476(82)80686-0

The Journal of Pediatrics

17 September 2023

published in

1 reference

17 September 2017

101

1 reference

17 September 2017

4

1 reference

17 September 2017

487-494

1 reference

Principles of immunization as applied to poliomyelitis and influenza

17 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Control of Influenza and Poliomyelitis with Killed Virus Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

The Problems of Poliovirus Immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

7 January 2021

Informed consent: II.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Eradication of poliomyelitis in the United States. I. Live virus vaccine-associated and wild poliovirus disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Eradication of poliomyelitis in the United States. II. Experience with killed poliovirus vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Polio vaccination in Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Eradication of poliomyelitis in the United States: a commentary on the Salk reviews

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Recommendations for a National Policy on Poliomyelitis Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Rubella vaccination in the United States: a ten-year review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Controlling Rubella: Problems and Perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Benefit-cost analysis of rubella vaccination policy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Rubella immunization: progress, problems and potential solutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

RA27/3 rubella vaccine. A four-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Rubella, measles and mumps antibodies following vaccination of children. A potential rubella problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Rubella viraemia and antibody responses after rubella vaccination and reimmunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Current features of measles in the United States: feasibility of measles elimination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

The 'new' epidemiology of measles and rubella

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Development and Evaluation of the Moraten Measles Virus Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Present status of measles and rubella immunization in the United States: A medical progress report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Further attenuated live measles vaccines: The need for revised recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Epidemic Measles in a Highly Vaccinated Population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Additional evidence against measles vaccine administration to infants less than 12 months of age: Altered immune response following active/passive immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Polyvalent Pneumococcal-Polysaccharide Immunization of Patients with Sickle-Cell Anemia and Patients with Splenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Varicella Vaccination: Where Do We Go From Here?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Live vaccine used to prevent the spread of varicella in children in hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Safety and immunogenicity of a new Haemophilus influenzae type b vaccine in infants under one year of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2882%2980686-0

Properties and behavior of orally administered attenuated poliovirus vaccine

7 January 2021

2

1 reference

https://api.crossref.org/works/10.1016/S0022-3476(82)80686-0

17 September 2023

Informed Consent: I

7

1 reference

https://api.crossref.org/works/10.1016/S0022-3476(82)80686-0

17 September 2023

Informed Consent: III

9

1 reference

https://api.crossref.org/works/10.1016/S0022-3476(82)80686-0

Controversies in current immunization policy and practices: one physician's viewpoint

17 September 2023

24

1 reference

https://api.crossref.org/works/10.1016/S0022-3476(82)80686-0

17 September 2023

Identifiers

1 reference

17 September 2017

1 reference